{"id":919928,"date":"2025-12-15T18:03:15","date_gmt":"2025-12-15T23:03:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/"},"modified":"2025-12-15T18:03:15","modified_gmt":"2025-12-15T23:03:15","slug":"nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/","title":{"rendered":"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN FRANCISCO<\/span>, Dec. 15, 2025<\/span> \/PRNewswire\/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Tuesday, December 16, 2025 at 8:00 am ET \/ 5:00 am PT.\u00a0<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Nektar
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Conference Call <\/b>\n <\/p>\n

The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK<\/a>.<\/p>\n

The event, the press release and the slides will also be available on the events section of the Nektar website at https:\/\/ir.nektar.com\/events-and-presentations\/events<\/a>.\u00a0A replay of the webcast will be available for at least 30 days following the event.<\/p>\n

\n About Nektar Therapeutics<\/b>\n <\/p>\n

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials.<\/p>\n

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com<\/a>\u00a0and follow us on LinkedIn<\/a>.<\/p>\n

\n For Investors:
<\/b>Vivian Wu
628-895-0661<\/p>\n

Corey Davis,\u00a0Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com<\/a>
212-915-2577<\/p>\n

Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com<\/a>
212-915-3820<\/p>\n

\n For Media:<\/b>\n <\/p>\n

Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com<\/a>\u00a0<\/p>\n

\u00a0<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025-302642737.html<\/a><\/p>\n

SOURCE Nektar Therapeutics<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN FRANCISCO, Dec. 15, 2025 \/PRNewswire\/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Tuesday, December 16, 2025 at 8:00 am ET \/ 5:00 am PT.\u00a0 Conference Call The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK. The event, the press release and the slides will also be available on the events … <\/p>\n

Continue reading “Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-919928","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN FRANCISCO, Dec. 15, 2025 \/PRNewswire\/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Tuesday, December 16, 2025 at 8:00 am ET \/ 5:00 am PT.\u00a0 Conference Call The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK. The event, the press release and the slides will also be available on the events … Continue reading "Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T23:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025\",\"datePublished\":\"2025-12-15T23:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/\"},\"wordCount\":376,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/Nektar_Logo_v1.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/\",\"name\":\"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/Nektar_Logo_v1.jpg\",\"datePublished\":\"2025-12-15T23:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/Nektar_Logo_v1.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/Nektar_Logo_v1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/","og_locale":"en_US","og_type":"article","og_title":"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 - Market Newsdesk","og_description":"PR Newswire SAN FRANCISCO, Dec. 15, 2025 \/PRNewswire\/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Tuesday, December 16, 2025 at 8:00 am ET \/ 5:00 am PT.\u00a0 Conference Call The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK. The event, the press release and the slides will also be available on the events … Continue reading \"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-15T23:03:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025","datePublished":"2025-12-15T23:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/"},"wordCount":376,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/","name":"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg","datePublished":"2025-12-15T23:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=919928"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919928\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=919928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=919928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=919928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}